Stallergenes Greer Ltd is a United States-based holding company. The Company is a healthcare company. Its engaged in the diagnosis and treatment of allergies through the development and commercialization of allergen immunotherapy products and services. It also engaged in distribution of products and services.

Employees

Sector

Pharmaceuticals

More about the company

Real-time Euronext Paris			5-day change	1st Jan Change
- ^EUR	-.--%		+0.14%	+29.68%

06/10	Stallergenes Greer Ltd Announces Appointment of Anette Erika Weber as Director, Effective September 24, 2026	CI
29/09	Stallergenes Greer Ltd Announces Termination of Andreas Christian Amrein as Director, Effective September 15, 2026	CI

Market Cap	724M 808M 666M 603M 1.13B 76.76B 1.15B 7.94B 3.19B 40.38B 3.03B 2.97B 127B	P/E 2024 *	-	P/E 2025	-
Enterprise Value	724M 808M 666M 603M 1.13B 76.74B 1.15B 7.94B 3.19B 40.37B 3.03B 2.97B 127B	EV / Sales 2024 *	-	EV / Sales 2025	-
Free-Float	-	Yield 2024 *	-	Yield 2025	-

06/10	Stallergenes Greer Ltd Announces Appointment of Anette Erika Weber as Director, Effective September 24, 2026	CI
29/09	Stallergenes Greer Ltd Announces Termination of Andreas Christian Amrein as Director, Effective September 15, 2026	CI
17/07	Stallergenes Greer Ltd Reports Earnings Results for the Full Year Ended December 31, 2025	CI
05/05	Stallergenes Greer Ltd Announces Termination of Nicola Lamacchia as Director on April 30, 2026	CI
05/05	Stallergenes Greer Ltd Appoints Andreas Christian Amrein as Director on April 30, 2026	CI
07/10/25	Stallergenes Greer Ltd Reports Earnings Results for the Full Year Ended December 31, 2024	CI
08/04/25	Stallergenes Greer Ltd Announces Termination of Nunzio Michele Antonelli as Director	CI
09/01/25	European Commission Approves the Extension of the Indication of Palforzia to the Treatment of Toddlers with Confirmed Peanut Allergy	CI
01/10/24	Stallergenes Greer Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	CI
12/07/23	Nestle Reportedly May Sell Peanut Allergy Therapy to Stallergenes	CI
25/05/23	Stallergenes Greer Ltd Initiates European Paediatric Phase III Study with Staloral Birch	CI
06/05/22	Stallergenes Greer Ltd Reports Earnings Results for the Full Year Ended December 31, 2021	CI
17/01/22	Stallergenes Greer Strengthens Precision Medicine Approach in Allergen Immunotherapy with Imperial College London Research Collaboration	CI

26/01/18	Stallergenes Greer : comments on share price movement	PU
05/10/17	Stallergenes Greer : 04/10/2017 - Director/PDMR Shareholding. Released October 4, 2017	PU
04/10/17	Stallergenes Greer : 03/10/2017 - Director/PDMR Shareholding	PU
19/06/17	Stallergenes Greer : First real-world evidence shows long term benefits of sublingual immunotherapy to control allergic rhinitis and potentially prevent allergic asthma	PU
03/05/17	Stallergenes Greer : NOTIFICATION TO SHAREHOLDERS OF ANNUAL GENERAL MEETING ON 8 JUNE 2017	PU

Stallergenes Greer Stock

Stocks

STAGR

GB00BZ21RF93

Pharmaceuticals

Valuation: Stallergenes Greer

Latest news: Stallergenes Greer

Press Releases: Stallergenes Greer

News in other languages: Stallergenes Greer

Managers and Directors: Stallergenes Greer

Specialty & Advanced Pharmaceuticals

Financials

Company Profile

06/11/23	AB Science : Le secteur pharmaceutique signe un accord de branche sur la transition écologique
17/05/19	Stallergenes Greer : radiation du titre ce jour
17/05/19	Stallergenes Greer : fin de partie à la Bourse de Paris
14/05/19	EN DIRECT DES MARCHES : EDF, Vinci, Ipsen, Europlasma, Erytech, Bayer, Volkswagen...
14/05/19	Trump, la carotte après le bâton

Manager	Title	Age	Since
Andreas Amrein CEO	Chief Executive Officer	-	01/04/2025
Amer Jaber COO	Chief Operating Officer	-	01/01/2019
Daniel Smith CTO	Chief Tech/Sci/R&D Officer	-	11/04/2016

Director	Title	Age	Since
Francesco Pietro Crispino BRD	Director/Board Member	-	07/05/2019
Nicola Lamacchia BRD	Director/Board Member	-	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
STALLERGENES GREER	-.--%	+0.14%	-	-	0
ELI LILLY AND COMPANY	+3.19%	+11.31%	+67.86%	+150.58%	1,224B
JOHNSON & JOHNSON	-0.73%	+3.56%	+44.51%	+85.81%	662B
ABBVIE INC.	+1.41%	+3.24%	+29.22%	+107.83%	514B
ROCHE HOLDING AG	+0.42%	+2.88%	+54.92%	+69.67%	388B
MERCK & CO., INC.	+2.18%	+2.93%	+73.30%	+45.62%	361B
NOVARTIS AG	+1.12%	+3.80%	+35.82%	+59.72%	302B
ASTRAZENECA PLC	+6.96%	+7.55%	+11.15%	+37.89%	271B
AMGEN INC.	+1.15%	+6.09%	+59.59%	+77.06%	249B
GILEAD SCIENCES, INC.	+3.06%	+9.38%	+44.11%	+119.47%	205B
Average	+1.75%	+2.35%	+46.72%	+83.74%	417.68B
Weighted average by Cap.	+1.62%	+3.04%	+51.01%	+98.66%

	2023	2024 *
Net sales	-	-
Net income	-4.51M -5.03M -4.14M -3.76M -7.02M -478M -7.15M -49.43M -19.84M -251M -18.88M -18.48M -792M	-
Net Debt	24.35M 27.19M 22.4M 20.29M 37.94M 2.58B 38.65M 267M 107M 1.36B 102M 99.87M 4.28B	-